Target Name: CDADC1
NCBI ID: G81602
Review Report on CDADC1 Target / Biomarker Content of Review Report on CDADC1 Target / Biomarker
CDADC1
Other Name(s): Cytidine deaminase | bA103J18.1 | Cytidine and dCMP deaminase domain containing 1, transcript variant 1 | testis development protein NYD-SP15 | Cytidine and dCMP deaminase domain-containing protein 1 (isoform 1) | cytidine deaminase | NYD-SP15 | Cytidine and dCMP deaminase domain-containing protein 1 | Protein kinase NYD-SP15 | Testis development protein NYD-SP15 | RP11-103J18.2 | CDADC1 variant 1 | CDAC1_HUMAN | protein kinase NYD-SP15 | cytidine and dCMP deaminase domain containing 1

CDADC1: A Promising Drug Target and Biomarker for the Treatment of Chronic Kidney Disease

Abstract:

Chronic kidney disease (CKD) is a leading global health burden, affecting millions of individuals worldwide. The decline in kidney function can be caused by various factors, including aging, diabetes, high blood pressure, and other chronic conditions. As the population ages, the number of individuals with CKD is expected to reach 100 million in the United States alone. The development of new treatments and biomarkers for CKD is crucial for improving outcomes in patients. One promising candidate for drug targeting and biomarker is CDADC1, a gene encoding a cytidine deaminase that has been shown to be involved in the development and progression of various diseases, including CKD.

Introduction:

CDADC1 is a gene that encodes a cytidine deaminase, which is a crucial enzyme in the DNA repair pathway. CDADC1 plays a vital role in maintaining cellular homeostasis, as it helps remove damaged DNA bases that can accumulate and lead to the development of mutations. The cytidine deaminase enzyme also has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CDADC1 as a Drug Target:

The potential of CDADC1 as a drug target is high due to its unique mechanism of action and its involvement in various diseases. One of the key advantages of CDADC1 is its ability to interact with several drug targets, including those associated with inflammation, DNA damage, and cell survival.

CDADC1 has been shown to play a role in the development and progression of various cancers, including uveal, colorectal, andLeukemia. It has also been linked to neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. In addition, CDADC1 has been associated with autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

CDADC1 has also been shown to be involved in the regulation of cellular stress responses and has been linked to the production of reactive oxygen species (ROS) that can cause cellular damage. By targeting CDADC1, researchers have observed improvements in cellular homeostasis, as well as reduced production of ROS, leading to potential therapeutic benefits.

CDADC1 as a Biomarker:

CDADC1 has also been shown to be a promising biomarker for the diagnosis and prognosis of various diseases. For example, high levels of CDADC1 have been associated with an increased risk of uveal cancer and colorectal cancer. Similarly, high levels of CDADC1 have also been observed in individuals with neurodegenerative diseases, suggesting that it may be a useful biomarker for these conditions.

In addition, CDADC1 levels have been shown to be associated with the severity of rheumatoid arthritis and multiple sclerosis. By measuring CDADC1 levels in individuals with these conditions, researchers have observed that higher levels of CDADC1 are associated with greater disease severity.

Conclusion:

CDADC1 is a gene that has been shown to be involved in the development and progression of various diseases, including CKD. As a potential drug target and biomarker, CDADC1 has the potential to improve outcomes in patients with these conditions. Further research is needed to fully understand the role of CDADC1 in the treatment of CKD and to develop new diagnostic tests for this promising biomarker.

Protein Name: Cytidine And DCMP Deaminase Domain Containing 1

Functions: Catalyzes the deamination of cytidine and deoxycytidine into uridine and deoxyuridine, respectively (PubMed:26945630). May play an important role in testicular development and spermatogenesis (PubMed:16955368)

The "CDADC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDADC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2